A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin
S315 was generally safe and well tolerated by healthy subjects. Pharmacokinetic data suggest that S315 serum neutralizing activity is an order of magnitude greater than that attained by eDAT. The results of this study support continued development of S315 as a replacement for eDAT to address critical global supply issues. Clinical Trials Registration. NCT04075175.
Authors
- J. Sullivan-Bolyai
- Mark S. Klempner
- Ronald Goldwater
- Elise Dunzo
- Rebecca Cannon
- Kenya Prince Cohane
- Yang Wang (ORCID: https://orcid.org/0000-0002-5554-8247)
- Lois B. Allen
- Kathleen StCyr
Institutions
- University of Massachusetts Chan Medical School (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1093/infdis/jiae499
- Citations
- 5
- Primary Topic
- Diphtheria, Corynebacterium, and Tetanus
- Type
- article
- Field-Weighted Citation Impact
- 3.09